 |
 |
Date Announced: 10 Nov 2012
Yellow laser to treat a range of retinal diseases.
CHICAGO, Illinois, – November 10, 2012 – QUANTEL Medical has announced U.S. Food and Drug Administration (FDA) 510(k) market clearance of its SupraScan 577 Laser, an ophthalmic laser system for treating a wide range of retinal diseases. The SupraScan 577 uniquely combines three of the most clinically sought-after components in a retina laser – 577nm yellow wavelength, pattern-scanning, and MicroPulse™ tissue-sparing laser emission modes.
Mr. Jean-Marc Gendre, CEO of Quantel Medical, commented, "We are proud to have passed this regulatory milestone. Quantel was the first company in the world to bring to market a solid-state green retina laser in 1993, followed by a solid-state yellow retina laser in 2008.
Today’s announcement of 510(k) clearance for the SupraScan 577, the most advanced solid-state yellow scanning retina laser allows Quantel USA to offer a market-changing solution to retina specialists in the U.S.”
The clinical absorption characteristics of the 577nm yellow wavelength, specifically high absorption in oxyhemoglobin and low absorption in xanthophyll pigments, coupled with the ability to efficiently transmit through opaque ocular media have made it the wavelength of choice for retina treatments. Quantel’s SupraScan 577 is the first yellow laser on the market capable of pattern scanning delivery in both conventional and tissue-sparing MicroPulse modes available in the U.S.
E-mail: lhall@quantelusa.com
Web Site: www.quantel-medical.com
| © 2024 SPIE Europe |
|
